Hemodilution Modulates the Time of Onset and Rate of Fibrinolysis in Human and Rabbit Plasma

Compared with crystalloid or albumin, HES solutions enhance fibrinolysis by decreasing clot strength and decreasing the time of onset of fibrinolysis. Further studies are warranted to determine whether the fluid administered to patients with VADs can impact hemorrhagic and thrombotic morbidity.